KalVista Pharmaceuticals to be Acquired by Chiesi Group for $1.9 Billion in All-Cash Deal
Summary
KalVista Pharmaceuticals has entered into a definitive agreement to be acquired by Chiesi Group for $27.00 per share in cash, valuing the company at approximately $1.9 billion.
Key Events
-
Definitive Merger Agreement Signed
KalVista Pharmaceuticals has entered into an Agreement and Plan of Merger with Chiesi Farmaceutici S.p.A. and its subsidiary, Skyline Merger Sub, Inc.
-
All-Cash Acquisition at Premium
Chiesi will acquire all outstanding shares of KalVista for $27.00 per share in cash, representing an approximate total equity value of $1.9 billion. This price offers a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026, and is above the 52-week high of $21.305.
-
Board Unanimously Approves Transaction
The Boards of Directors of both Chiesi and KalVista have unanimously approved the acquisition.
-
Expected Closing in Q3 2026
The transaction is anticipated to close in the third quarter of 2026, subject to customary closing conditions, including the tender of a majority of outstanding shares and regulatory approvals (HSR Act, Germany, Italy).
Analysis
This 8-K filing officially announces the definitive agreement for Chiesi Group to acquire KalVista Pharmaceuticals. The all-cash offer of $27.00 per share represents a significant premium over the current trading price and is notably above the company's 52-week high of $21.305, providing immediate and substantial value to shareholders. The transaction, valued at approximately $1.9 billion, is a major positive development for shareholders, offering immediate liquidity and a substantial return. The acquisition is not subject to a financing condition, reducing execution risk, and is expected to close in Q3 2026, pending regulatory approvals and majority share tender.
At the time of this filing, KALV was trading at $26.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $985.5M. The 52-week trading range was $9.83 to $21.31. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.